Up-to-date List of Clindamycin Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Clindamycin Medical Research Studies

RankStatusStudy
1 Recruiting Adjunctive Clindamycin for Cellulitis: Clinical Trial Comparing Flucloxacillin With or Without Clindamycin for the Treatment of Limb Cellulitis (C4C Trial).
Condition: Cellulitis
Interventions: Drug: Flucloxacillin and Clindamycin;   Drug: Flucloxacillin and placebo
Outcome Measures: Improvement based on a composite of systemic and local features;   Decrease in pain;   Quality of life;   Physiological recovery
2 Recruiting Comparison Between Oral Clindamycin Vs Metronidazole for the Treatment of Abnormal Vaginal Flora in High Risk Pregnancies
Conditions: Abnormal Vaginal Flora;   Clindamycin Vs Metronidazole;   High Risk Pregnancies for Preterm Labor
Interventions: Drug: Clindamycin;   Drug: Metronidazole
Outcome Measures: To compare the efficacy between oral Clindamycin Vs Metronidazole in the eradication of abnormal vaginal flora;   The prevalence of adverse effects;   The prevalence of late abortions and preterm deliveries;   Assessing the correlation between Nugent score , physical examination and Ph indicators
3 Recruiting Safety and Pharmacokinetics of Clindamycin in Pediatric Subjects With BMI ≥ 85th Percentile
Conditions: Bacterial Infections;   Obesity
Intervention: Drug: Clindamycin
Outcome Measures: Clearance (Cl);   Volume of distribution (Vd);   Area under the curve (AUCtau);   Oral apparent clearance (Cl/F);   Oral apparent volume of distribution (V/F);   Number of Adverse Events
4 Unknown  A Study Comparing Combination Clindamycin Phosphate/Tretinoin Gel Alone Versus With Benzoyl Peroxide Foaming Cloths for Facial Acne
Condition: Acne Vulgaris
Interventions: Drug: Clindamycin phosphate 1.2%/tretinoin 0.025% gel alone;   Drug: Clindamycin phosphate 1.2%/tretinoin 0.025% gel plus benzoyl peroxide 6% foaming cloths
Outcome Measures: Change in PGA scores of patients using combination Clindamycin phosphate 1.2%/tretinoin 0.025% gel with or without benzoyl peroxide 6% foaming cloths for facial acne;   Change in Postinflammatory hyperpigmentation score at each study visit and from baseline to final visit.;   Total number of adverse events.;   Change in Subject Self Assessment Scoring Scale;   Change in Acne-Specific Quality of Life Questionnaire (Acne-QoL)
5 Recruiting Clindamycin to Reduce Preterm Birth in a Low Resource Setting
Conditions: Pregnancy;   Prematurity;   Preterm Birth;   Bacterial Vaginosis
Interventions: Drug: Clindamycin;   Drug: Placebo
Outcome Measures: Preterm birth prior to 37 weeks;   Preterm birth prior to 34 weeks;   Late Miscarriage;   Low Birth weight;   Very Low birth Weight;   Neonatal complications through 42 days after delivery;   Maternal complications through 42 days postpartum;   The utility of vaginal pH tests for identification of women at elevated risk for preterm delivery
6 Recruiting Asymptomatic Colonization With S. Aureus After Therapy With Linezolid or Clindamycin for Acute Skin Infections
Conditions: Skin Diseases, Bacterial;   Abscess
Interventions: Biological: Linezolid;   Biological: Clindamycin
Outcome Measures: The presence of Staphylococcus aureus after treatment with linezolid versus Clindamycin;   Clinical response of skin infections to treatment;   The type of of Staphylococcus aureus present at the diagnosis will be compared to the type of Staphylococcus aureus present after treatment
7 Recruiting Comparison of the Efficacy and Safety of Clindamycin + Benzoyl Peroxide Formulation With Azelaic Acid Formulation in the Treatment of Acne Vulgaris
Condition: Acne Vulgaris
Interventions: Drug: Clindamycin + BPO;   Drug: Azelaic acid
Outcome Measures: Change from Baseline of inflammatory lesion counts at Week 4;   Change from Baseline of lesion counts;   Change from Baseline of lesions by Investigator's Static Global Assessment (ISGA);   Time to 50% reduction in total lesion count;   Change from Baseline of local tolerability as assessed by investigator;   Subject's global change assessment (SGCA) of skin;   Change from Baseline of local tolerability as assessed by subject;   Subject satisfaction score at Week 12;   Measured adherence to study medication at Week 12;   Quality of Life Assessments;   Number of treatment related adverse events (AEs) and serious adverse events (SAEs)
8 Unknown  Evaluation of Fosmidomycin and Clindamycin in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria
Condition: Malaria
Intervention: Drug: Fosmidomycin and Clindamycin
Outcome Measures: Cure rate; cure rate
9 Recruiting To Compare the Efficacy and Safety of Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel of CHL Versus DUAC® Gel
Condition: Acne Vulgaris
Interventions: Drug: Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel;   Drug: DUAC® Gel;   Drug: Placebo
Outcome Measures: Mean percent change from baseline to week 11 (study Day 77) for inflammatory (papules and pustules) lesions.;   Mean percent change from baseline to week 11 in the non-inflammatory lesion count;   Proportion of subjects with a clinical response of "success" at week 11
10 Unknown  Evaluate Efficacy, Tolerability & Safety of Combination of Clindamycin and Ketoconazole for the Treatment of Mixed-Type Vaginosis, Bacterial Vaginosis and Candidiasis
Conditions: Candidiasis;   Bacterial Vaginosis
Interventions: Drug: Clindamycin 100mg and Ketoconazole 400mg;   Drug: Tetracycline 100mg and Amphotericin B 50mg
Outcome Measures: Efficacy based on cure rate evaluated by clinical and laboratory criteria.;   Tolerability based on adverse events reports and patient's information;   Safety based on adverse events reports and laboratory criterion
11 Recruiting Assessing the Necessity of Prescribing Antibiotics (Clavulin or Clindamycin Versus Placebo) Post-peritonsillar Abscess Drainage
Condition: Peritonsillar Abscess
Interventions: Drug: Clavulin;   Drug: Randomization to Placebo;   Drug: Clindamycin
Outcome Measure: Re-accumulation of the patient's peri-tonsillar abscess
12 Unknown  Treatment of Chorioamnionitis After Delivery
Condition: Chorioamnionitis
Interventions: Drug: saline;   Drug: ampicillin gentamicin;   Drug: Ampicillin gentamicin Clindamycin;   Drug: ampicillin gentamicin Clindamycin
Outcome Measure: To determine the courses of antibiotics needed after vaginal delivery and after cesareans in pregnancies complicated by chorioamnionitis.
13 Recruiting Antibiotic Safety (SCAMP)
Condition: Complicated Intra Abdominal Infections
Interventions: Drug: ampicillin and metronidazole and gentamicin;   Drug: ampicillin and gentamicin and Clindamycin;   Drug: gentamicin and Piperacillin- tazobactam;   Drug: standard of care antibiotics and metronidazole
Outcome Measures: Death;   Number of participants with therapeutic success at Day 30 and Day 90
14 Unknown  Randomized Controlled Trial of Antibiotics in the Management of Children With Community-Acquired Skin and Soft Tissue Abscess Undergoing Incision and Drainage
Conditions: Skin and Soft Tissue Abscess;   Methicillin-resistant Staphylococcus Aureus (MRSA) Infection
Intervention: Drug: Oral Clindamycin
Outcome Measures: The primary objective is to measure clinical resolution of skin abscess at routine follow-up visit 10-14 days post operation.;   Secondary outcomes measured include incidence of additional skin and soft tissue infections in patient and in household contacts as determined by healthcare provider. Compliance to antibiotic regime will also be assessed at this time.
15 Not yet recruiting Orthognathic Surgery and Postoperative Antibiotic Use
Condition: Dentofacial Deformity
Intervention: Drug: Cefazolin, Cephalexin, Clindamycin
Outcome Measures: Rate of infection;   Side effect from antibiotic use
16 Not yet recruiting Prophylactic Antibiotics for Manual Removal of Retained Placenta in Vaginal Birth: a Randomized Controlled Trial
Condition: Endometritis
Interventions: Drug: Antibiotic prophylaxis;   Drug: Ampicillin;   Drug: Gentamycin;   Drug: Clindamycin
Outcome Measures: Endometritis rate;   Puerperal fever
17 Recruiting Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus
Condition: Staphylococcal Infection
Interventions: Drug: Clindamycin;   Drug: Trimethoprim-sulfamethoxazole (TS);   Drug: Placebo
Outcome Measures: Clinical cure, defined as absence of clinical failure.;   Efficacy outcome: clinical cure of recurrences or relapses of SSTI.;   Safety outcomes: adverse events; and adverse events that are treatment limiting.
18 Recruiting PK of Antistaphylococcal Antibiotics in Infants (NICHD-2012-02-Staph Trio)
Condition: Systemic Infection
Intervention: Drug: Antibiotic
Outcome Measures: Pharmacokinetic concentrations in plasma will be measured at a central lab using a validated bioanalytical assay. Plasma samples will be drawn according to specific schedules for each drug;   Safety review will be performed through monitoring of adverse events each day that the infant is on study
19 Recruiting Skin Rash Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients
Conditions: Colorectal Cancer;   Head and Neck Cancer
Interventions: Drug: Doxycycline;   Drug: Hydrocortisone 1% cream;   Other: Sunscreen;   Other: Moisturizer;   Drug: Clindamycin;   Drug: Medrol-dose pack (Steroid)
Outcome Measures: Incidence of Rash;   Quality of Life (QOL);   Adherence to treatment regimen;   Progression Free Survival
20 Recruiting A Comparative Evaluation of the Safety and Efficacy of Daptomycin Versus Standard of Care in Pediatric Subjects Two - Seventeen Years of Age With Bacteremia Caused by Staphylococcus Aureus
Condition: Bacteremia
Interventions: Drug: Daptomycin;   Drug: Comparator (Vancomycin, Semi-synthetic penicillin, First-generation cephalosporins, Clindamycin)
Outcome Measures: Safety of daptomycin measured by the incidence of treatment-emergent adverse events, vital signs, echocardiogram (if performed) and clinical laboratory tests, use of concomitant medications,physical and neurological exam results.;   Efficacy of daptomycin will be based on Investigator's assessment of clinical response (cure, improved, failure or non-evaluable) at the Test of Cure (TOC) visit.

These studies may lead to new treatments and are adding insight into Clindamycin etiology and treatment.

A major focus of Clindamycin research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Clindamycin

privacy policy